Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Drug-Eluting Stents - Global Market Trends, Developments and Investment Opportunities 2026-2034

globenewswire.com
ABT Abbott's XIENCE Sierra Everolimus stent launch in India is mentioned as contributing to market expansion, indicating a positive development for the company within the growing drug-eluting stents market. BSX Boston Scientific Corporation is listed as a major player in the competitive landscape of the drug-eluting stents market, suggesting its involvement and potential growth in this expanding industry.

Drug-Eluting Stents - Global Market Trends, Developments and Investment Opportunities 2026-2034 Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Drug-Eluting Stents Market Report by Coating, Drug, Stent Platform, Generation, Application, End User, and Region ?2026-2034?" has been added to ResearchAndMarkets.com's offering.

The global drug-eluting stents market size, valued at USD 9.2 Billion in 2025, is projected to reach USD 14.5 Billion by 2034, growing at a CAGR of 5.03% from 2026 to 2034. This growth is largely driven by the increasing prevalence of cardiovascular diseases.

DRUG-ELUTING STENTS MARKET ANALYSIS:

Implementation of Next-Generation Drugs

Next-gen drug-eluting stents employ advanced drugs like biolimus and zotarolimus, increasing efficacy in preventing restenosis. Abbott's XIENCE Sierra Everolimus stent was launched in India in May 2024, contributing to market expansion.

Expanded Use in Peripheral Artery Disease

Drug-eluting stents are increasingly used for peripheral artery disease, broadening their application beyond coronary arteries. Cook Medical's April 2024 contract with the U.S. DoD to supply implantable devices exemplifies this trend.

Increasing Focus on Complex Lesions

The demand for drug-eluting stents to treat complex coronary lesions is rising. Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System, receiving FDA Breakthrough Device Designation in June 2024, underscores this growth area.

GLOBAL DRUG-ELUTING STENTS INDUSTRY SEGMENTATION

Our report provides in-depth analysis across key market segments, including coating, drug, stent platform, generation, application, and end user, with detailed forecasts for 2026-2034.

Breakup by Coating:

Polymer-free coatings, aimed at minimizing inflammation and enhancing medication delivery, hold the largest market share.

Breakup by Drug:

Each drug offers distinct benefits, from minimizing arterial narrowing to improving blood flow, thus driving market diversity.

Breakup by Stent Platform:

Cobalt-chromium stents, with durable and flexible designs, lead in demand, enhancing cardiovascular treatment outcomes.

Breakup by Generation:

Successive generations bring advancements in safety and efficacy, with 4th gen stents promoting faster recovery.

Breakup by Application:

Coronary artery disease remains the core focus, with stents helping maintain artery patency and reduce repeat procedures.

Breakup by End User:

Hospitals dominate as primary end-users, utilizing these devices extensively for cardiovascular interventions.

Breakup by Region:

North America's advanced healthcare infrastructure and technology adoption solidify its market leadership.

COMPETITIVE LANDSCAPE

A detailed analysis of the competitive landscape and profiles of major companies is included, showcasing key players like Abbott, B. Braun SE, and Boston Scientific Corporation.

KEY QUESTIONS ANSWERED IN THIS REPORT:

Key Attributes

Companies Featured:

For more information about this report visit https://www.researchandmarkets.com/r/132vm3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment